Additionally, a phase I PD-L1 based vaccination in multiple myeloma (NCT03042793) is ongoing, and a phase I/II trial that targeted both IDO- and PD-L1-specific T cells in combination with Nivolumab is running in metastatic melanoma (NCT03047928). This evidence concerns the gene CD274 and AL amyloidosis.